Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published as Ann Surg Oncol Early Release 10.1245/ASO.2003.03.010 on November 10, 2003

Annals of Surgical Oncology 10:1184-1190 (2003)
© 2003 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Damdinsuren, B.
Right arrow Articles by Monden, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Damdinsuren, B.
Right arrow Articles by Monden, M.
Related Collections
Right arrow Cell growth

ORIGINAL ARTICLES

Interferon-ß Is More Potent Than Interferon-{alpha} in Inhibition of Human Hepatocellular Carcinoma Cell Growth When Used Alone and in Combination With Anticancer Drugs

Bazarragchaa Damdinsuren, MD, Hiroaki Nagano, PhD, Masato Sakon, PhD, Motoi Kondo, PhD, Tameyoshi Yamamoto, MD, Koji Umeshita, PhD, Keizo Dono, PhD, Shoji Nakamori, PhD and Morito Monden, PhD

From the Department of Surgery and Clinical Oncology (E2), Graduate School of Medicine, Osaka University, Osaka, Japan.

Correspondence: Address correspondence and reprint requests to: Masato Sakon, PhD, Department of Surgery and Clinical Oncology (E2), Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita, Osaka 565–0871, Japan; Fax: 81-6-6879-3259; E-mail: msakon{at}surg2.med osaka-u.ac.jp

Background: The prognosis of advanced hepatocellular carcinoma (HCC) is extremely poor, but promising effects of chemotherapies combined with interferon (IFN) have been reported.

Methods: To develop more effective combination therapies for HCC, we compared the antiproliferative effects of IFN-{alpha} and IFN-ß in combination with various cytotoxic drugs on hepatoma cell lines using MTT assay and isobologram analysis.

Results: IFN-ß was more potent than IFN-{alpha} in inhibiting the cell growth of all cell lines (P < .05, two-way ANOVA). PLC/PRF/5 was more sensitive to either IFN, than HLE and HuH7. Cell growth of all cell lines was inhibited in a dose-dependent manner by 5-fluorouracil (5-FU), cisplatin (CDDP), and doxorubicin (DOX), but the sensitivities of these cells were considerably different. As for IFN-{alpha}, synergistic effects were observed when combined with 5-FU and DOX on PLC/PRF/5 cells only, whereas IFN-ß showed synergistic effects with 5-FU and CDDP on HuH7 and PLC/PRF/5 cell lines.

Conclusion: The spectra of the antiproliferative activity and synergistic effect of IFN-ß when combined with anticancer drugs are more potent than those of IFN-{alpha}. Combinations of IFN-ß and anticancer drugs may provide a better treatment of HCC when combinations with IFN-{alpha} are ineffective.

Key Words: Interferon • Anticancer drug • Cell proliferation • HCC • Combination therapy




This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
G. Vitale, P. M. van Koetsveld, W. W. de Herder, K. van der Wansem, J. A. M. J. L. Janssen, A. Colao, G. Lombardi, S. W. J. Lamberts, and L. J. Hofland
Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells
Am J Physiol Endocrinol Metab, March 1, 2009; 296(3): E559 - E566.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Zitzmann, S. Brand, E. N. De Toni, S. Baehs, B. Goke, J. Meinecke, G. Spottl, H. H.H.D. Meyer, and C. J. Auernhammer
SOCS1 Silencing Enhances Antitumor Activity of Type I IFNs by Regulating Apoptosis in Neuroendocrine Tumor Cells
Cancer Res., May 15, 2007; 67(10): 5025 - 5032.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Benjamin, A. Khwaja, N. Singh, J. McIntosh, A. Meager, M. Wadhwa, C. Streck, C. Ng, A. M. Davidoff, and A. C. Nathwani
Continuous delivery of human type I interferons ({alpha}/{beta}) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model
Blood, February 1, 2007; 109(3): 1244 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Vitale, W. W. de Herder, P. M. van Koetsveld, M. Waaijers, W. Schoordijk, E. Croze, A. Colao, S. W.J. Lamberts, and L. J. Hofland
IFN-{beta} Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro
Cancer Res., January 1, 2006; 66(1): 554 - 562.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
H. P. Clark, W. F. Carson, P. V. Kavanagh, C. P. H. Ho, P. Shen, and R. J. Zagoria
Staging and Current Treatment of Hepatocellular Carcinoma
RadioGraphics, October 1, 2005; 25(suppl_1): S3 - S23.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Kondo, H. Nagano, H. Wada, B. Damdinsuren, H. Yamamoto, N. Hiraoka, H. Eguchi, A. Miyamoto, T. Yamamoto, H. Ota, et al.
Combination of IFN-{alpha} and 5-Fluorouracil Induces Apoptosis through IFN-{alpha}/{beta} Receptor in Human Hepatocellular Carcinoma Cells
Clin. Cancer Res., February 1, 2005; 11(3): 1277 - 1286.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Society of Surgical Oncology.